IL194267A - METHOD FOR CONCENTRATING A COMPOSITION CONTAINING ARYL SULPHATASE A AND / OR FUNCTIONAL EQUIVALENT OF A PART OR ANALOGUE - Google Patents

METHOD FOR CONCENTRATING A COMPOSITION CONTAINING ARYL SULPHATASE A AND / OR FUNCTIONAL EQUIVALENT OF A PART OR ANALOGUE

Info

Publication number
IL194267A
IL194267A IL194267A IL19426708A IL194267A IL 194267 A IL194267 A IL 194267A IL 194267 A IL194267 A IL 194267A IL 19426708 A IL19426708 A IL 19426708A IL 194267 A IL194267 A IL 194267A
Authority
IL
Israel
Prior art keywords
analogues
concentrating
composition
functionally equivalent
equivalent part
Prior art date
Application number
IL194267A
Other languages
English (en)
Hebrew (he)
Other versions
IL194267A0 (en
Original Assignee
Shire Pharmaceuticals Ireland Ltd
Zymenex As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Pharmaceuticals Ireland Ltd, Zymenex As filed Critical Shire Pharmaceuticals Ireland Ltd
Publication of IL194267A0 publication Critical patent/IL194267A0/en
Publication of IL194267A publication Critical patent/IL194267A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01061—Hydroxymethylbilane synthase (2.5.1.61)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01024—Alpha-mannosidase (3.2.1.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Water Supply & Treatment (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL194267A 2006-04-04 2008-09-22 METHOD FOR CONCENTRATING A COMPOSITION CONTAINING ARYL SULPHATASE A AND / OR FUNCTIONAL EQUIVALENT OF A PART OR ANALOGUE IL194267A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200600488 2006-04-04
DKPA200600922 2006-07-05
PCT/DK2007/000177 WO2007112757A2 (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide

Publications (2)

Publication Number Publication Date
IL194267A0 IL194267A0 (en) 2011-08-01
IL194267A true IL194267A (en) 2015-10-29

Family

ID=38472949

Family Applications (4)

Application Number Title Priority Date Filing Date
IL194267A IL194267A (en) 2006-04-04 2008-09-22 METHOD FOR CONCENTRATING A COMPOSITION CONTAINING ARYL SULPHATASE A AND / OR FUNCTIONAL EQUIVALENT OF A PART OR ANALOGUE
IL211905A IL211905A0 (en) 2006-04-04 2011-03-24 A process for concentration of a polypeptide
IL235982A IL235982A0 (en) 2006-04-04 2014-11-30 A process for concentrating a polypeptide
IL241654A IL241654B (en) 2006-04-04 2015-09-16 Compositions comprising recombinant arylsulfatase and uses thereof for the treatment of metachromatic leukodystrophy

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL211905A IL211905A0 (en) 2006-04-04 2011-03-24 A process for concentration of a polypeptide
IL235982A IL235982A0 (en) 2006-04-04 2014-11-30 A process for concentrating a polypeptide
IL241654A IL241654B (en) 2006-04-04 2015-09-16 Compositions comprising recombinant arylsulfatase and uses thereof for the treatment of metachromatic leukodystrophy

Country Status (20)

Country Link
US (6) US20090246187A1 (https=)
EP (4) EP2628746B1 (https=)
JP (6) JP2009532394A (https=)
KR (3) KR101504969B1 (https=)
CN (1) CN105233276A (https=)
AU (2) AU2007234195B2 (https=)
BR (1) BRPI0709737A2 (https=)
CA (3) CA2644642C (https=)
DK (1) DK2628746T3 (https=)
ES (3) ES2928096T3 (https=)
HU (1) HUE042402T2 (https=)
IL (4) IL194267A (https=)
MX (1) MX2008012748A (https=)
NO (3) NO347673B1 (https=)
NZ (7) NZ607595A (https=)
PL (3) PL2631242T3 (https=)
PT (1) PT2628746T (https=)
SI (1) SI2628746T1 (https=)
WO (1) WO2007112757A2 (https=)
ZA (2) ZA200805346B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713904B1 (en) 2004-01-30 2016-06-29 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulfatase a
HUE042402T2 (hu) * 2006-04-04 2019-06-28 Chiesi Farm Spa Eljárás polipeptid töményítésére
CA2790786C (en) * 2010-02-24 2019-09-24 Zymenex A/S Process for production and purification of recombinant lysosomal alpha-mannosidase
LT2588130T (lt) * 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
JP6073783B2 (ja) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
HRP20191923T1 (hr) * 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku arilsulfataze a u cns
PT3103469T (pt) 2010-06-25 2021-03-04 Shire Human Genetic Therapies Administração de agentes terapêuticos no snc
US10336992B2 (en) 2011-07-08 2019-07-02 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase A
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
NZ707753A (en) * 2012-11-13 2019-07-26 Chiesi Farm Spa Purification of recombinant human galactocerebroside β-galactosidase (rhgalc)
CA2893609A1 (en) * 2012-12-11 2014-06-19 Centogene Ag Method for the diagnosis of metachromatic leukodystrophy
CN112126634A (zh) 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
AU2015236340B2 (en) * 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
EP3676375A4 (en) * 2017-08-31 2021-04-07 Green Cross Corporation PROCESS FOR PURIFYING A SULFATASE PROTEIN
KR102290596B1 (ko) * 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2041280A1 (en) 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) * 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
DE69901536T2 (de) 1998-01-27 2003-01-16 Hemebiotech A/S, Hellerod Behandlung von akuter intermittierender porphyria oder anderen porphyrischen krankheiten
IL140155A (en) * 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
DK2270044T3 (en) * 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
US6537777B1 (en) 1998-07-27 2003-03-25 Hemebiotech A/S Human porphobilinogen deaminase sequences
AUPQ026799A0 (en) * 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
JP2003505057A (ja) 1999-07-27 2003-02-12 ヘム−バイオテック エイ／エス ｒｈＰＢＧＤの製造及び急性間欠性ポルフィリン症（ＡＩＰ）及び他のポルフィリン症の患者を処置するための新規な治療方法
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2429210A1 (en) 2000-11-15 2002-05-23 Jason C. Goodrick Expression system for recombinant proteins
WO2002099092A2 (en) * 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
AU2002317700A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
EP1402014A1 (en) 2001-06-29 2004-03-31 Hemebiotech A/S A process for purification of recombinant porphobilinogen deaminase
US7232670B2 (en) * 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
WO2003066669A2 (en) * 2002-02-04 2003-08-14 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
CH694697A5 (de) 2004-01-29 2005-06-15 Koelbl Engineering Und Consult Gummimehl-enthaltende Elastomerlegierungen.
EP1713904B1 (en) * 2004-01-30 2016-06-29 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulfatase a
WO2005094874A1 (en) 2004-04-01 2005-10-13 Zymenex A/S Medical use of alpha-mannosidase
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
HUE042402T2 (hu) * 2006-04-04 2019-06-28 Chiesi Farm Spa Eljárás polipeptid töményítésére

Also Published As

Publication number Publication date
US20090246187A1 (en) 2009-10-01
US20180289777A1 (en) 2018-10-11
AU2008229659B2 (en) 2013-01-31
JP2014051503A (ja) 2014-03-20
BRPI0709737A2 (pt) 2011-07-26
IL194267A0 (en) 2011-08-01
ZA200809540B (en) 2019-09-25
ES2744499T3 (es) 2020-02-25
NO20082510L (no) 2008-10-31
KR101504969B1 (ko) 2015-03-24
JP5878152B2 (ja) 2016-03-08
JP2009532394A (ja) 2009-09-10
EP2631242B1 (en) 2022-08-03
KR20150103339A (ko) 2015-09-09
CA2644642C (en) 2016-01-26
JP2014058521A (ja) 2014-04-03
HUE042402T2 (hu) 2019-06-28
AU2008229659A1 (en) 2008-10-23
IL241654A0 (en) 2015-11-30
JP2013236633A (ja) 2013-11-28
US20120076767A1 (en) 2012-03-29
JP5384232B2 (ja) 2014-01-08
EP2004672A2 (en) 2008-12-24
IL241654B (en) 2019-02-28
EP2100898A1 (en) 2009-09-16
IL235982A0 (en) 2015-01-29
AU2007234195A1 (en) 2007-10-11
CA2632528C (en) 2022-07-12
EP2100898B1 (en) 2019-06-19
NO20211305A1 (no) 2008-10-31
NZ607595A (en) 2014-10-31
US9713634B2 (en) 2017-07-25
PL2100898T3 (pl) 2019-11-29
EP2631242A2 (en) 2013-08-28
SI2628746T1 (sl) 2019-04-30
NO20084776L (no) 2008-10-31
NZ597548A (en) 2013-08-30
JP2009273469A (ja) 2009-11-26
DK2628746T3 (en) 2019-04-01
US20170202927A1 (en) 2017-07-20
EP2004672B1 (en) 2015-08-19
CN105233276A (zh) 2016-01-13
EP2628746B1 (en) 2019-01-09
NZ623123A (en) 2015-04-24
NZ571610A (en) 2011-07-29
WO2007112757A3 (en) 2008-02-28
NZ582045A (en) 2011-07-29
PT2628746T (pt) 2019-04-23
KR20090018894A (ko) 2009-02-24
EP2631242A3 (en) 2013-10-02
MX2008012748A (es) 2009-01-07
US8809055B2 (en) 2014-08-19
NZ568728A (en) 2011-09-30
IL211905A0 (en) 2011-05-31
CA2632528A1 (en) 2007-10-11
US20140314735A1 (en) 2014-10-23
NO346368B1 (no) 2022-06-27
JP2016104000A (ja) 2016-06-09
US20160193304A1 (en) 2016-07-07
NZ588903A (en) 2012-08-31
ES2713488T3 (es) 2019-05-22
AU2007234195B2 (en) 2013-02-07
PL2631242T3 (pl) 2023-03-20
ZA200805346B (en) 2018-11-28
PL2628746T3 (pl) 2019-07-31
CA2882501A1 (en) 2007-10-11
EP2628746A2 (en) 2013-08-21
NO347673B1 (no) 2024-02-19
EP2628746A3 (en) 2014-03-19
WO2007112757A2 (en) 2007-10-11
CA2882501C (en) 2021-09-07
ES2928096T3 (es) 2022-11-15
CA2644642A1 (en) 2007-10-11
KR20140057678A (ko) 2014-05-13

Similar Documents

Publication Publication Date Title
IL194267A (en) METHOD FOR CONCENTRATING A COMPOSITION CONTAINING ARYL SULPHATASE A AND / OR FUNCTIONAL EQUIVALENT OF A PART OR ANALOGUE
EP2079300A4 (en) BIRD DETERGENT AND METHOD OF INSTALLING THE SAME
EP2077607A4 (en) LAMINATED CORE OF A ROTOR AND METHOD FOR THE PRODUCTION THEREOF
IL250678A0 (en) Compounds and methods for repressing pcsk9 gene expression
EP2164433A4 (en) ANCHORED RESPIRATORY TRACT IMPLANTS AND METHODS USING THE SAME
IL199211A0 (en) Dental attachment assembly and method
EP1991185A4 (en) AIRWAY IMPLANT SENSORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
EP1983931A4 (en) HIGHLY FLEXIBLE STENT AND PROCESS FOR PRODUCING THE SAME
PL2018230T3 (pl) Instalacja powlekająca i przynależny sposób eksploatacji
IL197916A0 (en) Stabilizing compositions and methods for extraction of ridonucleic acid
EP2064300A4 (en) ADHESIVE FABRIC COMPOSITIONS AND RELATED METHODS
EP2121195A4 (en) ROTOR ARRANGEMENT AND CONNECTION METHOD THEREFOR
EP2142721A4 (en) KUNSTRINDEN EXTERNAL WALL CLADDING AND MANUFACTURING METHOD THEREFOR
ZA201103640B (en) Method and composition for the treatment of a substrate
IL192564A0 (en) Composition and method of use thereof
GB0619803D0 (en) Lockerbank structure and method of assembly
TWI372762B (en) Amino derivatives of b-homoandrostanes and b-heteroandrostanes
GB0623058D0 (en) Game system and method
EP1982721A4 (en) PROCESS FOR STABILIZING S-ADENOSYL-L-METHIONINE AND STABILIZED COMPOSITION
IL178698A0 (en) A coating and method of preparing same
EP2094279A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF INFLUENZA
GB2453905B (en) Board material and method of manufacture
GB0600261D0 (en) Composition and method
GB2439211B (en) Label arrangement and method of manufacture
GB2436130B (en) A vane arrangement and a method of making vane arrangement

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed